Systematic identification of genomic markers of drug sensitivity in cancer cells

Cytoscape: A software Environment for integrated models of biomolecular interaction networks

Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888

Regularization and Variable Selection Via the Elastic Net

Zou, H., & Hastie, T. (2005) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.1467-9868.2005.00503.x · Cited by 20,957

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

A comparison of normalization methods for high density oligonucleotide array data based on variance and bias

Bolstad, B. M., Irizarry, R. A., Åstrand, M., & Speed, T. P. (2003) · Bioinformatics · doi:10.1093/bioinformatics/19.2.185 · Cited by 8,328

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720

Clustering by Passing Messages Between Data Points

Frey, B. J., & Dueck, D. (2007) · Science · doi:10.1126/science.1136800 · Cited by 6,855

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087

An Integrated Approach to Anti-Cancer Drug Sensitivity Prediction

Berlow, N., Haider, S., Wan, Q., Geltzeiler, M. N., Davis, L. E., Keller, C., & Pal, R. (2014) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2014.2321138 · Cited by 33

RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients

Muniz, V. P., Askeland, R. W., Zhang, X., Reed, S. M., Tompkins, V. S., Hagen, J., McDowell, B. D., Button, A. M., Smith, B. J., Weydert, J. A., et al. (2013) · Genes & Cancer · doi:10.1177/1947601913501074 · Cited by 33

In silico modeling predicts drug sensitivity of patient-derived cancer cells

Pingle, S. C., Sultana, Z., Pastorino, S., Jiang, P., Mukthavaram, R., Chao, Y. S., Bharati, I. S., Nomura, N., Makale, M., Abbasi, T., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-128 · Cited by 33

Recent advances in breast cancer cell line research

Sharma, M. P., Shukla, S., & Misra, G. (2024) · International Journal of Cancer · doi:10.1002/ijc.34849 · Cited by 33

Anticancer drug response prediction integrating multi-omics pathway-based difference features and multiple deep learning techniques

Wu, Y., Chen, M., & Qin, Y. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012905 · Cited by 42

Integrative epigenomic and genomic filtering for methylation markers in hepatocellular carcinomas

Shen, J., LeFave, C. V., Sirosh, I., Siegel, A. B., Tycko, B., & Santella, R. M. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0105-1 · Cited by 32

Systems biology for molecular life sciences and its impact in biomedicine

Medina, M. Á. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1109-z · Cited by 32

Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles

Aksoy, B. A., Demir, E., Babur, Ö., Wang, W., Jing, X., Schultz, N. D., & Sander, C. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu164 · Cited by 31

Pathway-based dissection of the genomic heterogeneity of cancer hallmarks’ acquisition with SLAPenrich

Iorio, F., García‐Alonso, L., Brammeld, J. S., Martincorena, I., Willé, D. R., McDermott, U., & Sáez-Rodríguez, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-25076-6 · Cited by 32

A framework for large-scale metabolome drug profiling links coenzyme A metabolism to the toxicity of anti-cancer drug dichloroacetate

Dubuis, S., Ortmayr, K., & Zampieri, M. (2018) · Communications Biology · doi:10.1038/s42003-018-0111-x · Cited by 35

MCT2 mediates concentration-dependent inhibition of glutamine metabolism by MOG

Fets, L., Driscoll, P. C., Grimm, F., Jain, A., Nunes, P. M., Gounis, M., Doglioni, G., Papageorgiou, G., Ragan, T. J., Campos, S., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0136-y · Cited by 31

Dissecting PARP inhibitor resistance with functional genomics

Pettitt, S. J., & Lord, C. J. (2019) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2019.03.001 · Cited by 32

A benchmark-driven approach to reconstruct metabolic networks for studying cancer metabolism

Jamialahmadi, O., Hashemi‐Najafabadi, S., Motamedian, E., Romeo, S., & Bagheri, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006936 · Cited by 32

Novel Aptamers Selected on Living Cells for Specific Recognition of Triple-Negative Breast Cancer

Camorani, S., Granata, I., Collina, F., Leonetti, F., Cantile, M., Botti, G., Fedele, M., Guarracino, M. R., & Cerchia, L. (2020) · iScience · doi:10.1016/j.isci.2020.100979 · Cited by 32

Logic Gates Based on DNA Aptamers

Andrianova, M. S., & Kuznetsov, A. E. (2020) · Pharmaceuticals · doi:10.3390/ph13110417 · Cited by 32

The hidden switches underlying RORα-mediated circuits that critically regulate uncontrolled cell proliferation

Shin, D., Kim, I. S., Lee, J. M., Shin, S., Lee, J., Baek, S. H., & Cho, K. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju023 · Cited by 30

Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma

Yang, J., Annala, M., Ji, P., Wang, G., Zheng, H., Codgell, D., Du, X., Fang, Z., Sun, B., Nykter, M., et al. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0076-2 · Cited by 33

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers

Kotani, H., Adachi, Y., Kitai, H., Tomida, S., Bando, H., Faber, A. C., Yoshino, T., Voon, D. C., Yano, S., & Ebi, H. (2018) · Oncogene · doi:10.1038/s41388-017-0035-9 · Cited by 32

Discovery of two-level modular organization from matched genomic data via joint matrix tri-factorization

Chen, J., & Zhang, S. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky440 · Cited by 31

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasetsPreprint

Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J. M., Beaver, C., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/604447 · Cited by 32

A systematic assessment of deep learning methods for drug response prediction: from in vitro to clinical applications

Shen, B., Feng, F., Li, K., Lin, P., Ma, L., & Li, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac605 · Cited by 31

Functions and inhibitors of CHK1 in cancer therapy

Jiang, K., Deng, M., Du, W., Liu, T., Li, J., & Zhou, Y. (2024) · Medicine in Drug Discovery · doi:10.1016/j.medidd.2024.100185 · Cited by 33

Preventive Evolutionary Medicine of Cancers

Hochberg, M., Frédéric Thomas, A., Assénat, E., & Hibner, U. (2012) · Evolutionary Applications · doi:10.1111/eva.12033 · Cited by 31

Targeted therapies for advanced Ewing sarcoma family of tumors

Jiang, Y., Ludwig, J. A., & Jankú, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.03.008 · Cited by 31

CIB1 contributes to oncogenic signalling by Ras via modulating the subcellular localisation of sphingosine kinase 1

Zhu, W., Gliddon, B. L., Jarman, K. E., Moretti, P. A. B., Tin, T., Parise, L. V., Woodcock, J. M., Powell, J. A., Ruszkiewicz, A. R., Pitman, M. R., et al. (2016) · Oncogene · doi:10.1038/onc.2016.428 · Cited by 31

Driver gene classification reveals a substantial overrepresentation of tumor suppressors among very large chromatin-regulating proteins

Waks, Z., Weissbrod, O., Carmeli, B., Norel, R., Utro, F., & Goldschmidt, Y. (2016) · Scientific Reports · doi:10.1038/srep38988 · Cited by 31

Systematic Analysis of Drug Vulnerabilities Conferred by Tumor Suppressor Loss

Ding, H., Zhao, J., Zhang, Y. L., Yu, J., Liu, M., Li, X., Xu, L., Lin, M., Liu, C., He, Z., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.043 · Cited by 28

An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer

Wang, H., Lv, Q., Xu, Y., Cai, Z., Zheng, J., Cheng, X., Dai, Y., Janne, P. A., Ambrogio, C., & Köhler, J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.10.012 · Cited by 32

A TP53 mutation model for the prediction of prognosis and therapeutic responses in head and neck squamous cell carcinoma

Shi, C., Liu, S., Tian, X., Wang, X., & Gao, P. (2021) · BMC Cancer · doi:10.1186/s12885-021-08765-w · Cited by 32

Q-omics: Smart Software for Assisting Oncology and Cancer Research

Lee, J., Kim, Y., Jin, S., Yoo, H., Jeong, S., Jeong, E., & Yoon, S. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0169 · Cited by 31

PharmacoDB 2.0: improving scalability and transparency of in vitro pharmacogenomics analysis

Feizi, N., Nair, S. K., Smirnov, P., Beri, G., Eeles, C. B., Esfahani, P. N., Nakano, M., Tkachuk, D., Mammoliti, A., Gorobets, E., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab1084 · Cited by 31

Computational estimation of quality and clinical relevance of cancer cell lines

Trastulla, L., Noorbakhsh, J., Vazquez, F., McFarland, J., & Iorio, F. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211017 · Cited by 31

The kinase PLK1 promotes the development of Kras / Tp53 -mutant lung adenocarcinoma through transcriptional activation of the receptor RET

Kong, Y., Allison, D. B., Zhang, Q., He, D., Li, Y., Mao, F., Li, C., Li, Z., Zhang, Y., Wang, J., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abj4009 · Cited by 29

The Level of Ets-1 Protein Is Regulated by Poly(ADP-Ribose) Polymerase-1 (PARP-1) in Cancer Cells to Prevent DNA Damage

Legrand, A. J., Choul‐li, S., Spriet, C., Idziorek, T., Vicogne, D., Drobecq, H., Dantzer, F., Villeret, V., & Aumercier, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055883 · Cited by 31

Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma

Litvin, O., Schwartz, S., Wan, Z., Schild, T., Rocco, M., Oh, N. L., Chen, B.-J., Goddard, N. L., Pratilas, C. A., & Pe’er, D. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.030 · Cited by 29

Precision Cancer Medicine in the Acoustic Dispensing Era: Ex Vivo Primary Cell Drug Sensitivity Testing

Kulesskiy, E., Saarela, J., Turunen, L., & Wennerberg, K. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215618869 · Cited by 29

A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma

Kaufman, J. M., Yamada, T., Park, K., Timmers, C. D., Amann, J. M., & Carbone, D. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1639 · Cited by 31

Knowledge elicitation via sequential probabilistic inference for high-dimensional prediction

Daee, P., Peltola, T., Soare, M., & Samuel Kaski, A. (2017) · Machine Learning · doi:10.1007/s10994-017-5651-7 · Cited by 34

Using drug response data to identify molecular effectors, and molecular “omic” data to identify candidate drugs in cancer

Reinhold, W. C., Varma, S., Rajapakse, V. N., Luna, A., Sousa, F. G., Kohn, K. W., & Pommier, Y. G. (2014) · Human Genetics · doi:10.1007/s00439-014-1482-9 · Cited by 31

New strategies for targeting drug combinations to overcome mutation-driven drug resistance

Wang, L., Wang, H., Song, D., Xu, M., & Liebmen, M. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.11.002 · Cited by 30

Cytotoxic and toxicogenomic effects of silibinin in bladder cancer cells with different TP53 status

de Oliveira, D. T., Sávio, A. L. V., Marcondes, J. P. D. C., Barros, T. M. B., Barbosa, L. C., Salvadori, D. M. F., & da Silva, G. N. (2016) · Journal of Biosciences · doi:10.1007/s12038-016-9654-5 · Cited by 30

Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response

Jernström, S., Hongisto, V., Leivonen, S., Due, E. U., Tadele, D. S., Edgren, H., Kallioniemi, O., Perälä, M., Mælandsmo, G. M., & Sahlberg, K. K. (2017) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s115600 · Cited by 32

Sparse regression Chebyshev polynomial interval method for nonlinear dynamic systems under uncertainty

Li, C., Chen, B., Peng, H., & Zhang, S. (2017) · Applied Mathematical Modelling · doi:10.1016/j.apm.2017.06.008 · Cited by 30

Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties

Dasgupta, A., Trucco, M. M., Rainusso, N. C., Bernardi, R. J., Shuck, R. L., Kurenbekova, L., Loeb, D. M., & Yustein, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.20467 · Cited by 33

Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer

Wang, Y., Zhang, L., Wei, Y., Huang, W., Li, L., Wu, A., Dastur, A., Greninger, P., Bray, W. M., Zhang, C., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.06.011 · Cited by 30

Exploiting Replication Stress as a Novel Therapeutic Intervention

Martin, J. C., Hoegel, T. J., Lynch, M. L., Woloszynska‐Read, A., Melendy, T., & Ohm, J. E. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0651 · Cited by 32

Predicting Cancer Drug Response In Vivo by Learning an Optimal Feature Selection of Tumour Molecular Profiles

Nguyen, L. C., Naulaerts, S., Bomane, A., Bruna, A., Ghislat, G., & Ballester, P. J. (2021) · Biomedicines · doi:10.3390/biomedicines9101319 · Cited by 36

Advances in the Treatment of Pediatric Bone Sarcomas

Grohar, P. J., Janeway, K. A., Maese, L. D., & Schiffman, J. D. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175378 · Cited by 30

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma

Liu, K., Geng, Y., Wang, L., Xu, H., Zou, M., Li, Y., Zhao, Z., Chen, T., Xu, F., Sun, L. D., et al. (2022) · Molecular Oncology · doi:10.1002/1878-0261.13279 · Cited by 29

A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma

Ramos, L., Truong, S., Zhai, B., Joshi, J., Ghaidi, F., Lizardo, M. M., Shyp, T., Kung, S. H. Y., Rezakhanlou, A. M., Oo, H. Z., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3897 · Cited by 31

Resistance to HSP90 inhibition involving loss of MCL1 addiction

Busacca, S., Law, E. W. P., Powley, I. R., Proia, D. A., Sequeira, M., Quesne, J. P. C. L., Klabatsa, A., Edwards, J. M., Matchett, K. B., Luo, J., et al. (2015) · Oncogene · doi:10.1038/onc.2015.213 · Cited by 29

Combining Targeted Agents With Modern Radiotherapy in Soft Tissue Sarcomas

Wong, P., Houghton, P. J., Kirsch, D. G., Finkelstein, S. E., Monjazeb, A. M., Xu‐Welliver, M., Dicker, A. P., Ahmed, M. M., Vikram, B., Teicher, B. A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju329 · Cited by 31

TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas

Leicht, D. T., Kausar, T., Wang, Z., Ferrer-Torres, D., Wang, T. D., Thomas, D. G., Lin, J., Chang, A. C., Lin, L., & Beer, D. G. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000229 · Cited by 30

On the pharmacogenetics of non-small cell lung cancer treatment

Santarpía, M., Rolfo, C. D., Peters, G. J., León, L. G., & Giovannetti, E. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1141894 · Cited by 30

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin

Cruickshank, M. N., Ford, J., Cheung, L. C., Heng, J., Singh, S., Wells, J. E., Failes, T. W., Arndt, G. M., Smithers, N. N., Prinjha, R. K., et al. (2016) · Leukemia · doi:10.1038/leu.2016.165 · Cited by 30

Primary glioblastoma cells for precision medicine: a quantitative portrait of genomic (in)stability during the first 30 passages

Baskaran, S., Mayrhofer, M., Kultima, H. G., Bergström, T., Elfineh, L., Cavelier, L. B., Isaksson, A., & Nelander, S. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy024 · Cited by 30

Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network

Liu, L., Chen, X., Hu, C., Zhang, D., Shao, Z., Jin, Q., Yang, J., Xie, H., Liu, B., Hu, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26783-w · Cited by 30

Systems Biology Approaches to a Rational Drug Discovery Paradigm

Prathipati, P., & Mizuguchi, K. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150826114524 · Cited by 32

What general conclusions can we draw from kinase profiling data sets?

Sutherland, J. J., Gao, C., Cahya, S., & Vieth, M. (2013) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2012.12.023 · Cited by 29

High-Resolution Mutational Profiling Suggests the Genetic Validity of Glioblastoma Patient-Derived Pre-Clinical Models

Yost, S. E., Pastorino, S., Rozenzhak, S., Smith, E. N., Chao, Y. S., Jiang, P., Kesari, S., Frazer, K. A., & Harismendy, O. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056185 · Cited by 29

Advances in Therapy for Pediatric Sarcomas

Weiss, A. R., Gill, J. B., Goldberg, J., Lagmay, J., Spraker‐Perlman, H. L., Venkatramani, R., & Reed, D. R. (2014) · Current Oncology Reports · doi:10.1007/s11912-014-0395-z · Cited by 28

A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors

Rechem, C. V., Black, J. C., Greninger, P., Zhao, Y., Donado, C. A., Burrowes, P. D., Ladd, B., Christiani, D. C., Benes, C. H., & Whetstine, J. R. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1159 · Cited by 29

Challenges in validating candidate therapeutic targets in cancer

Settleman, J. E., Sawyers, C. L., & Hunter, T. R. (2018) · eLife · doi:10.7554/elife.32402 · Cited by 32

RWEN: response-weighted elastic net for prediction of chemosensitivity of cancer cell lines

Basu, A. B., Mitra, R., Liu, H., Schreiber, S. L., & Clemons, P. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty199 · Cited by 32

Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition

Verginelli, F., Pisacane, A. M., Gambardella, G., D’Ambrosio, A., Candiello, E., Ferrio, M., Panero, M., Casorzo, L., Benvenuti, S., Cascardi, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22643-w · Cited by 30

Studies of Glyoxalase 1-Linked Multidrug Resistance Reveal Glycolysis-Derived Reactive Metabolite, Methylglyoxal, Is a Common Contributor in Cancer Chemotherapy Targeting the Spliceosome

Alhujaily, M. M., Abbas, H., Xue, M., de la Fuente, A., Rabbani, N., & Thornalley, P. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.748698 · Cited by 29

Raman spectroscopy biochemical characterisation of bladder cancer cisplatin resistance regulated by FDFT1: a review

Kanmalar, M., Sani, S. F. A., Kamri, N. I. N. B., Said, N. A. B. M., Jamil, A. H. A., Kuppusamy, S., Mun, K.-S., & Bradley, D. A. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00307-x · Cited by 29

Combi-seq for multiplexed transcriptome-based profiling of drug combinations using deterministic barcoding in single-cell droplets

Mathur, L., Szalai, B., Du, N. H., Utharala, R., Ballinger, M., Landry, J. J. M., Ryckelynck, M., Beneš, V., Sáez-Rodríguez, J., & Merten, C. A. (2022) · Nature Communications · doi:10.1038/s41467-022-32197-0 · Cited by 27

IRS2 Copy Number Gain, KRAS and BRAF Mutation Status as Predictive Biomarkers for Response to the IGF-1R/IR Inhibitor BMS-754807 in Colorectal Cancer Cell Lines

Huang, F., Han, C. L., Greer, A. L., Hillerman, S. M., Reeves, K. A., Hurlburt, W. W., Cogswell, J. P., Patel, D., Qi, Z., Fairchild, C. A., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0794-t · Cited by 29

The renewed battle against RAS-mutant cancers

Zhang, F., & Cheong, J. K. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2155-8 · Cited by 30

Cancer genome sequencing: Understanding malignancy as a disease of the genome, its conformation, and its evolution

Patel, L. R., Nykter, M., Chen, K., & Zhang, W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.10.018 · Cited by 28

RETRA exerts anticancer activity in Ewing’s sarcoma cells independent of their TP53 status

Sonnemann, J., Grauel, D., Blümel, L., Hentschel, J., Marx, C., Blumrich, A., Focke, K., Becker, S., Wittig, S., Schinkel, S., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.02.016 · Cited by 28

Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer

Nichols, A. C., Black, M. D., Yoo, J. J., Pinto, N. C., Fernandes, A. D., Haibe‐Kains, B., Boutros, P. C., & Barrett, J. W. (2014) · BMC Pharmacology and Toxicology · doi:10.1186/2050-6511-15-66 · Cited by 28

Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer Therapy

Belizário, J. E., Sangiuliano, B. A., Pérez-Sosa, M., Neyra, J. M., & Moreira, D. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00312 · Cited by 28

Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma

Tomska, K., Kurilov, R., Lee, K.-S., Hüllein, J., Lukas, M., Sellner, L., Walther, T., Wagner, L., Oleś, M., Brors, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30509-3 · Cited by 28

Identifying Cancer Driver lncRNAs Bridged by Functional Effectors through Integrating Multi-omics Data in Human Cancers

Zhang, Y., Liao, G., Bai, J., Zhang, X., Xu, L., Deng, C., Yan, M., Xie, A., Luo, T., Long, Z., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.030 · Cited by 28

Precision Medicine and its Role in the Treatment of Sepsis: A Personalised View

Lazăr, A. E., Georgescu, A. M., Vitin, A. A., & Azamfirei, L. (2019) · The Journal of Critical Care Medicine · doi:10.2478/jccm-2019-0017 · Cited by 28

Dissecting the Tumor–Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach

Chen, G. M., Azzam, A., Ding, Y., Barrett, D. M., Grupp, S. A., & Tan, K. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3888 · Cited by 28

A statistical framework for assessing pharmacological responses and biomarkers using uncertainty estimates

Wang, D. Y. Q., Hensman, J. J., Kutkaite, G., Toh, T. S., Galhoz, A., GDSC Screening Team, Lightfoot, H. W., Yang, W., Soleimani, M., Barthorpe, S., et al. (2020) · eLife · doi:10.7554/elife.60352 · Cited by 28

A pan-cancer survey of cell line tumor similarity by feature-weighted molecular profiles

Sinha, R., Luna, A., Schultz, N. D., & Sander, C. (2021) · Cell Reports Methods · doi:10.1016/j.crmeth.2021.100039 · Cited by 28

Synthetic lethal gene pairs: Experimental approaches and predictive models

Tang, S., Gökbağ, B., Fan, K., Shao, S., Huo, Y., Wu, X., Cheng, L., & Li, L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.961611 · Cited by 28

New Strategies in Ewing Sarcoma: Lost in Translation?

Arnaldez, F. I., & Helman, L. J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0633 · Cited by 30

Personalized Therapy for Breast Cancer: A Dream or a Reality?

Zardavas, D., Pugliano, L., & Piccart, M. J. (2013) · Future Oncology · doi:10.2217/fon.13.57 · Cited by 28

The Genome of the Chicken DT40 Bursal Lymphoma Cell Line

Molnár, J., Póti, Á., Pipek, O., Krzystanek, M., Kanu, N., Swanton, C., Tusnády, G., Szállási, Z., Csabai, I., & Szüts, D. (2014) · G3 Genes Genomes Genetics · doi:10.1534/g3.114.013482 · Cited by 28

Selective inhibition of N-linked glycosylation impairs receptor tyrosine kinase processing

Klaver, E. J., Zhao, P., May, M. M., Flanagan‐Steet, H. R., Freeze, H. H., Gilmore, R., Wells, L., Contessa, J. N., & Steet, R. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.039602 · Cited by 28

Systematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data

Nguyen, L. C., Dang, C. C., & Ballester, P. J. (2016) · F1000Research · doi:10.12688/f1000research.10529.2 · Cited by 29

QSAR-derived affinity fingerprints (part 2): modeling performance for potency prediction

Cortés‐Ciriano, I., Škuta, C., Bender, A., & Svozil, D. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00444-5 · Cited by 28

PaccMann: Prediction of anticancer compound sensitivity with multi-modal attention-based neural networksPreprint

Oskooei, A., Born, J., Manica, M., Subramanian, V., Sáez-Rodríguez, J., & Martínez, M. R. (2018) · arXiv (Cornell University) · doi:10.48550/arxiv.1811.06802 · Cited by 28

Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation

Feng, C., Ding, G., Jiang, H., Ding, Q., & Wen, H. (2014) · Tumor Biology · doi:10.1007/s13277-014-2981-y · Cited by 27

Molecular pathology of bone tumours: diagnostic implications

Puls, F., Niblett, A., & Mangham, D. C. (2013) · Histopathology · doi:10.1111/his.12275 · Cited by 27

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype

Saar, M., Zhao, H., Nolley, R., Young, S. R., Coleman, I. M., Nelson, P. S., Vessella, R. L., & Peehl, D. M. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.014 · Cited by 28

ATG9A loss confers resistance to trastuzumab via c-Cbl mediated Her2 degradation

Nunes, J., Zhang, H., Angelopoulos, N., Chhetri, J. B., Osipo, C., Grothey, A., Stebbing, J., & Giamas, G. (2016) · Oncotarget · doi:10.18632/oncotarget.8504 · Cited by 27

Cancer drug discovery: recent innovative approaches to tumor modeling

Lovitt, C. J., Shelper, T., & Avery, V. M. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1214562 · Cited by 27

The effect of Nullomer-derived peptides 9R, 9S1R and 124R on the NCI-60 panel and normal cell lines

Alileche, A., & Hampikian, G. (2017) · BMC Cancer · doi:10.1186/s12885-017-3514-z · Cited by 26

Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2

Vormoor, B. J., Schlosser, Y. T., Blair, H., Sharma, A. B., Wilkinson, S., Newell, D. R., & Curtin, N. J. (2017) · Oncotarget · doi:10.18632/oncotarget.21300 · Cited by 27

Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells

Kolluri, K. K., Alifrangis, C., Kumar, N., Ishii, Y., Price, S., Michaut, M., Williams, S., Barthorpe, S., Lightfoot, H. W., Busacca, S., et al. (2018) · eLife · doi:10.7554/elife.30224 · Cited by 30

Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells

Heuvel, J. P. V., Maddox, E., Maalouf, S. W., Reproducibility Project: Cancer Biology, Iorns, E. J., Tsui, R., Denis, A., Perfito, N., & Errington, T. M. (2018) · eLife · doi:10.7554/elife.29747 · Cited by 27

Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial

Kim, S., Sa, J., Oh, S., Kim, K., Hong, J., Kang, W., Kim, K.-M., & Lee, J. (2021) · Genome Medicine · doi:10.1186/s13073-021-00826-w · Cited by 22

Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets

Bi, G., Bian, Y., Liang, J., Yin, J., Li, R., Zhao, M., Huang, Y., Lu, T., Zhan, C., Fan, H. X., et al. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02889-0 · Cited by 29

Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing

Pietarinen, P. O., Pemovska, T., Kontro, M., Yadav, B., Mpindi, J. P., Andersson, E. I., Majumder, M. M., Kuusanmäki, H., Koskenvesa, P., Kallioniemi, O., et al. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.30 · Cited by 25

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950

Cell lines battle cancer

Weinstein, J. N. (2012) · Nature · doi:10.1038/483544a · Cited by 109

Pharmacogenomic profiling of cancer drugs

Aschheim, K. (2012) · Nature Biotechnology · doi:10.1038/nbt.2231 · Cited by 1

Cells line up to be characterized

Kirk, R. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.56 · Cited by 2

Integrative Statistical Inferences for Drug Sensitivity Biomarkers in CancerPreprint

Ullah, E., Shama, S., Muftah, N. A., Thompson, I. R., Rawi, R., Mall, R., & Bensmail, H. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/194670